Placebo Clinical Trial - Assessment of Cost-effectiveness in Two

Status Not yet recruiting

Clinical Trial Summary

Patients suffering from borderline personality disorder (BPD) are considered frequent utilizers of psychiatric emergency rooms and of psychiatric hospitalizations. Nonetheless, recent studies challenge the effectiveness of psychiatric hospitalizations in reducing BPD symptoms, and some have even indicated potentially harmful effects such as increasing suicide risk post-discharge. These findings highlight the importance of effective outpatient treatments for BPD patients in public psychiatric hospital settings. In this study we aim to assess the effectiveness and cost-effectiveness of two empirically-based treatments for BPD: dialectical behavior therapy (DBT) and dynamic deconstructive psychotherapy (DDP).

Clinical Trial Description

In this study we aim to assess the effectiveness and cost-effectiveness of two empirically-based treatments for BPD: dialectical behavior therapy (DBT) and dynamic deconstructive psychotherapy (DDP). Sixty-eight participants with BPD will be randomized to each of two treatment groups. Participants and therapists will be recruited from the Shalvata MHC, a 139‐bed psychiatric institution with outpatient units serving a population of more than 600,000 people in Israel. A blinded research assistant will administer primary and secondary outcome measures every 3 months during the 12 months of treatment and at the end of the 6-month naturalistic follow-up period after ending treatment with DDP or DBT. Therapist adherence will be systematically assessed in both treatments for 10% of sessions. Primary outcome measure will be comprised of the Incremental cost-effectiveness ratio (ICER), as assessed by estimating the healthcare utilization costs per incremental improvement in suicide severity. Secondary outcome measures will include BPD and depression symptom severity and quality of life. This study was submitted to the institutional review board of the Shalvata MHC in November 2019, and is expected to be approved by late Janury 2020. ;

Study Design

Related Conditions & MeSH terms

Borderline Personality Disorder
Personality Disorders
Placebo
Treatment 1:Dialectical Behavior Therapy (DBT)
Treatment 2:Dynamic Deconstructive Psychotherapy (DDP)

Clinical Trial Details

NCT number	NCT04309045
Study type	Interventional
Source	Shalvata Mental Health Center
Contact
Status	Not yet recruiting
Phase	N/A
Start date	April 1, 2020
Completion date	October 22, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04852315` - Acute Caffeine Ingestion on Futsal Performance	N/A
Completed	`NCT05427409` - Ingestion of Beta-alanine Effects in Well-trained Tennis Players	N/A
Completed	`NCT05425563` - Effects of Expectations on Negative Affect, Perceived Cognitive Effort, and Pain	N/A
Recruiting	`NCT05007561` - Understanding How Opioids Affect the Experiential and Neural Signatures of Social Experiences	Early Phase 1
Recruiting	`NCT03897998` - Neural Correlates of Hypoalgesia Driven by Observation	Phase 2
Recruiting	`NCT04851301` - Neural Mechanisms of Immersive Virtual Reality in Chronic Pain	Phase 1/Phase 2
Completed	`NCT04359147` - The Role of Stress Neuromodulators in Decision Making Under Risk and Selective Attention to Threat	N/A
Recruiting	`NCT05145764` - Suvorexant as an Adjunct to Buprenorphine in Persons Who Use Fentanyl	Phase 2
Completed	`NCT01167478` - Neurophysiological Reserve With Caffeine Manipulation	N/A
Completed	`NCT05337527` - Neuromuscular Responses to Acute Beetroot Ingestion in Women Older Adults	N/A
Terminated	`NCT01656577` - Pexacerfont for Stress-induced Food Craving	Phase 0
Completed	`NCT04361968` - Combining Animal-assisted Intervention and Placebo-induced Analgesia	N/A
Completed	`NCT03754062` - Pharmacological Modulation of Belief Salience	Phase 1
Not yet recruiting	`NCT04317157` - Placebo Effects Investigated by Different Experimental Designs	N/A
Completed	`NCT01361633` - The Cognitive Enhancing Effects of D-Cycloserine Among Non-Demented Elderly	Phase 2
Completed	`NCT05209126` - Impact of Beetroot Juice Ingestion on Female Rugby Performance	N/A
Completed	`NCT05521347` - Caffeine Supplementation Improves the Cognitive Abilities and Shooting Performance of Trained E-sports Players	N/A
Completed	`NCT04975360` - Delayed-release Bedtime Caffeine and Sleep Inertia Symptoms Immediately Upon Awakening	N/A
Completed	`NCT04671043` - Caffeine Ingestion to Counter the Exercise-mediated Fall in Glycaemia in Type 1 Diabetes	N/A
Completed	`NCT01011465` - The Biology of Resilience	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Assessment of Cost-effectiveness in Two Empirically-based Psychotherapies for Borderline Personality Disorder: A Randomized Controlled Trial

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms